UBX1325 averaged a 5.2 letter increase in best-corrected visual acuity at 24 weeks and a 5.5 letter increase at 36 weeks in the ASPIRE trial. With exception for the average of weeks 20 and 24, when it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback